Most notable was the evidence that the SMAD3 gene, which encodes a key regulatory protein in the transforming growth factor beta signalling pathway, may contribute to increased risk of breast cancer in BRCA2 mutation carriers. The gene discussed is SMAD3; the disease is breast carcinoma.